Clinical Trials Logo

Depression clinical trials

View clinical trials related to Depression.

Filter by:

NCT ID: NCT05741684 Completed - Depression Clinical Trials

iCBT and ABM for Reducing Depressive Symptoms in Firefighters

Start date: April 1, 2022
Phase: N/A
Study type: Interventional

The study aimed to examine the impact of a combined internet-delivered Cognitive Behavioral Therapy (iCBT) and Attention Bias Modification (ABM) intervention to reduce depressive symptoms in firefighters. The study was a randomized controlled trial carried out in Kunming, China, and involved the recruitment of 138 active firefighters as participants. The intervention lasted for an 8-week duration, during which participants participated in ABM exercises on alternating days and concurrently underwent four modules of iCBT courses delivered through a smartphone application.

NCT ID: NCT05732740 Completed - Depression Clinical Trials

Empower@Home:Connected - Feasibility and Preliminary Effect Study

Start date: January 17, 2023
Phase: N/A
Study type: Interventional

This single-group trial will evaluate the feasibility and preliminary effect of a novel group-based cognitive behavioral therapy program for older adults with elevated depressive symptoms. Participants will complete the program remotely in small groups.

NCT ID: NCT05731323 Completed - Clinical trials for Major Depressive Disorder

D-Cycloserine+iTBS PK Study

Start date: October 12, 2022
Phase: Phase 1
Study type: Interventional

Background & Rationale: Major Depressive Disorder (MDD) is a common and debilitating illness that that commonly does not respond to conventional treatments. Transcranial magnetic stimulation (TMS) and intermittent theta-burst stimulation (iTBS) are non-invasive neurostimulation treatments for depression that are Health Canada approved. These work by generating magnetic fields outside of the body to change the activity of brain cells to change how the brain works. They have a very favorable profile, with many patients experiencing improvement with minimal side effects. The investigators recently completed a study pairing iTBS with an FDA approved medication that was chosen because it might enhance iTBS improvements. This medication is called D-cycloserine, an old antibiotic that is rarely used in modern times. Years after it stopped being useful as an antibiotic, scientists recognized other properties that the molecule has, and it is some of these that make it interesting to pair with iTBS. When the investigators did so, they found that compared to iTBS with a placebo, participants who received iTBS+D-cycloserine were more likely to benefit from treatment. In this original study, all participants received a fixed dose of 100mg daily. This means that people of very different sizes could have had different drug levels, and the investigators do not know how that impacted outcomes. With this study, there will be no placebo condition because the purpose is to understand whether dosing according to weight matters. Research Question and Objectives: To describe the pharmacokinetic profile of 100mg oral D-cycloserine and weight-based oral D-cycloserine dosed 25mg/17.5kg among individuals with depression undergoing non-invasive intermittent theta-burst stimulation to the left dorsolateral prefrontal cortex (DLPFC) in Major Depressive Disorder.

NCT ID: NCT05728177 Completed - Clinical trials for Inhalation Aromatherapy

Effect of Inhalation Aromatherapy on Anxiety and Depressive Symptoms of Geriatric Patients With Parkinson's Disease

Start date: August 10, 2022
Phase: N/A
Study type: Interventional

The present study aims to: Investigate the effect of inhalation aromatherapy on anxiety and depressive symptoms of geriatric patients with Parkinson's disease. Research Hypothesis: Patients with Parkinson's disease who inhale aromatherapy will exhibit lower anxiety and depressive symptoms than those who didn't inhale it

NCT ID: NCT05728086 Completed - Depression Clinical Trials

Art Therapy to Address Hospital Clinician Burnout

CHArt
Start date: March 6, 2023
Phase: N/A
Study type: Interventional

A structured group art therapy intervention, comprising six 60 - 90-minute weekly workshops.

NCT ID: NCT05727358 Completed - Clinical trials for Acute Stroke Patients With Depression

Effectiveness of Group Acceptance and Commitment Therapy in Treating Acute Stroke Patients With Depression

Start date: August 1, 2018
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to discover the effectiveness of group-based Acceptance and Commitment Therapy (ACT) in treating depression for acute stroke patients. The main question[s] it aims to answer are: - Group-based ACT (G-ACT) could significantly reduce the depressive symptoms in patients with acute stroke, - the interventional efficacy could be maintained at 3-month follow-up - similar benefits would be observed for quality of life (QOL), sleep quality, psychological flexibility, cognitive fusion, and confidence. The patients included to the control group received usual care support in hospital, and the patients included to the intervention group received G-ACT and usual care support. the G-ACT treatment in this study comprised 7 sessions of 45-60 minutes and was administered throughout the course of the 4-week long trial.

NCT ID: NCT05724680 Completed - Depression Clinical Trials

Effectiveness of Cognitive Behavior Therapy for Persons With Depression

Start date: August 10, 2018
Phase: N/A
Study type: Interventional

This was a randomized controlled clinical trial (RCT) carried out in three different hospitals in Dhaka city, Bangladesh.

NCT ID: NCT05724511 Completed - Clinical trials for Cardiovascular Diseases

The Effect of Probiotics on Depression Syndrome and Risk Factors of Cardiovascular Disease in Hemodialysis Patients

Start date: February 27, 2023
Phase: Phase 4
Study type: Interventional

As the investigators know, only few researches focus on the effect of probiotics on depression in hemodialysis patients. Besides, probiotics also have benefit effect on dyslipidemia and hypertension in general population. Both of them are the risk factors of cardiovascular disease which is the major cause of death in hemodialysis patients. Therefore, this study looks for the effect of probiotics on depression syndrome and risk factors of cardiovascular disease in hemodialysis patients. This is a randomized controlled trial. All patients will be assigned at random to intervention group or control group. This study plans to recruit 70 hemodialysis patients and expects at least 30 patients in each group at the end of study period. The investigators provide probiotics (C. butyricum MIYAIRI 588) to intervention group and provide nothing to the control group. All patients need to maintain the lifestyle during study period. Genomic analysis of gut microbiota on patients' fecal samples will be used to evaluation their compliance.

NCT ID: NCT05720741 Completed - Depression Clinical Trials

Project THINK: Trial of a Brief Cognitive Restructuring Intervention

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

This project will involve testing a brief (~30 minute) digital intervention aimed at teaching youth the evidence-based strategy of changing unhelpful thoughts (i.e., cognitive restructuring). The investigators will test the intervention's efficacy compared to an active control condition. Participants (students in grades 5-10 in U.S. schools) will be asked to complete measures of mental health and well-being prior to the intervention as well as 1, 3, and 6-months after the intervention. If the intervention is found to be effective, its brevity and scalability would make it an invaluable resource for supplementing traditional psychotherapy and potentially preventing the onset of mental illness requiring specialized intensive care.

NCT ID: NCT05720637 Completed - Clinical trials for Major Depressive Disorder

The Efficacy and Cerebral Mechanism of Intradermal Acupuncture for Major Depressive Disorder

Start date: November 1, 2022
Phase: N/A
Study type: Interventional

Major depressive disorder (MDD) is highly prevalent, affecting nearly 4% of the global population. Pharmacotherapy is the frontline treatment recommended by the guideline, but it also has some limitations such as delayed onset, inadequate response, and drug resistance. Intradermal acupuncture (IA) is a method of using short indwelling needles retained under the skin to produce continuous stimulation for long-term efficacy. It has been reported that IA combination medication appears to be more valuable than medication alone in the treatment of MDD, however, there is a lack of high-quality clinical evidence.While several studies have proposed that manual or electroacupuncture can improve MDD symptoms by modulating brain networks, the cerebral mechanism of IA as superficial acupuncture for MDD has not been reported. Hence, investigators designed a multicentre randomized controlled trial to assess the clinical efficacy and safety of IA for MDD and preliminarily explore the potential therapeutic mechanisms for IA by functional magnetic resonance imaging (fMRI) .